GleamWall
中文EN

INVA Innoviva, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1080014 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.8%
TTM net income YoY51.9%
TTM EPS YoY41.6%
Revenue 3-yr CAGR14.7%
Net income 3-yr CAGR57.1%

Margins

Gross margin74.5%
Operating margin38.8%
Net margin44.1%
FCF margin41.6%
EBITDA margin—

Returns

ROE18.0%
ROA13.0%
ROIC (approx.)18.3%
Asset turnover0.30x

Leverage & solvency

Liabilities / assets26.0%
Debt / equity0.23x
Current ratio15.44x
Interest coverage8.64x

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio0.7%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue$411.33M$358.71M
Gross profit$307.67M$296.21M
R&D expense$30.60M$13.65M
SG&A expense$113.32M$115.69M
Operating income$163.75M$166.87M
Interest expense$16.70M$22.21M
Pretax income$326.86M$37.39M
Income tax$55.70M$14.00M
Net income$271.17M$23.39M
EPS (basic)4.020.37
EPS (diluted)3.300.36
Weighted avg. shares (diluted)84.76M74.19M
Balance sheet
Cash & equivalents$550.94M$304.96M
Inventory$39.17M$33.73M
Current assets$727.51M$554.31M
PP&E, net$1.55M$514,000
Goodwill$17.91M$17.91M
Intangibles$182.16M$208.43M
Total assets$1.64B$1.30B
Current liabilities$49.70M$236.08M
Short-term debt$0$192.03M
Long-term debt$257.73M$256.32M
Total debt$257.73M$448.34M
Total liabilities$462.32M$609.90M
Shareholders' equity$1.17B$691.16M
Net debt-$293.21M$143.38M
Shares outstanding74.64M62.66M
Cash flow statement
Operating cash flow$196.93M$188.69M
Capital expenditure$1.13M$270,000
Free cash flow$195.80M$188.42M
Investing cash flow$40.50M-$63.79M
Financing cash flow$8.55M-$13.45M
Stock-based compensation$9.45M$6.37M
Share buybacks$4.53M$14.78M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.